Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05007587 | Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC | unknown | Early Phase 1 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT03814447 | The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer | unknown | Early Phase 1 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04966143 | Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer | unknown | Early Phase 1 | 30 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04951141 | Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2021 | clinicaltrials |
| NCT04264078 | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04919460 | Research on Optimization and Evaluation of Oral Cancer Screening Methods | unknown | Early Phase 1 | 10,000 | Hunan Cancer HospitalOTHER | 0 | Jun 9, 2021 | clinicaltrials |
| NCT04919616 | An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 15 | Shanghai OriginCell Therapeutics Co., Ltd.INDUSTRY | 0 | Jun 9, 2021 | clinicaltrials |
| NCT02823691 | The MetNET-2 Trial(MetNET-2) | unknown | Early Phase 1 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | unknown | Early Phase 1 | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 0 | May 6, 2021 | clinicaltrials |
| NCT04841421 | Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors | unknown | Early Phase 1 | 30 | Sinotau Pharmaceutical GroupINDUSTRY | 0 | Apr 12, 2021 | clinicaltrials |
| NCT04801264 | Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 | unknown | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04702841 | CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors | unknown | Early Phase 1 | 8 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT04502797 | A Feasibility Study to Evaluate The Effect of the Electronic Patient Visit Assessment On Pain and Quality of Life for Patients With Head and Neck Cancer (HNC)(ePVA) | unknown | Early Phase 1 | 30 | New York UniversityOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03064282 | Prostatic Hyperplasia Treatment and Cancer Prevention | unknown | Early Phase 1 | 40 | Manchanda Medical ClinicOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT00790413 | Haploidentical Stem Cell Transplantation in Neuroblastoma | unknown | Early Phase 1 | 15 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04753918 | Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study | unknown | Early Phase 1 | 3 | Taoyuan General HospitalOTHER_GOV | 0 | Feb 15, 2021 | clinicaltrials |
| NCT04691349 | CAR-T for r/r Malignant Tumors in Children | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04439721 | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse(γδT) | unknown | Early Phase 1 | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04696705 | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | unknown | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT03961412 | A Family-based Intervention to Improve Pap Test Screening Among Under-screened Chinese American Immigrant Women | unknown | Early Phase 1 | 224 | University of Nevada, RenoOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04638270 | Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04639739 | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | unknown | Early Phase 1 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04626726 | Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626739 | CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | unknown | Early Phase 1 | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626752 | CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04570683 | Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas | unknown | Early Phase 1 | 30 | Bispebjerg HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | unknown | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04518774 | Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | unknown | Early Phase 1 | 8 | Beijing 302 HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04513431 | A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)(CRC) | unknown | Early Phase 1 | 18 | Ruijin HospitalOTHER | 0 | Aug 14, 2020 | clinicaltrials |
| NCT04503980 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | unknown | Early Phase 1 | 10 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04209712 | Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | unknown | Early Phase 1 | 6 | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaINDUSTRY | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04489862 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | unknown | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04417933 | Tumor Electric Fields Treatment System for Glioblastoma | unknown | Early Phase 1 | 5 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04412174 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04412889 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04129099 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04045847 | CD147-CART Cells in Patients With Recurrent Malignant Glioma. | unknown | Early Phase 1 | 31 | Xijing HospitalOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT03371992 | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC(NO3DEXPL) | unknown | Early Phase 1 | 25 | Nilogen OncosystemsINDUSTRY | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02077543 | Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma(ProTool) | unknown | Early Phase 1 | 150 | University Hospital, GrenobleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04315584 | FDG and FDOPA PET Demonstration of Functional Brain Abnormalities | unknown | Early Phase 1 | 5 | University of VirginiaOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT03790891 | Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT04226989 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | unknown | Early Phase 1 | 72 | He HuangOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04264039 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04251403 | Novel Approach to Surveillance of Gastric Lesions | unknown | Early Phase 1 | 10 | New York Presbyterian HospitalOTHER | 0 | Jan 31, 2020 | clinicaltrials |
| NCT03295916 | Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis(STOMP) | unknown | Early Phase 1 | 30 | Juravinski Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 16, 2021source: clinicaltrials